Posted on September 16, 2011 by Sitemaster
Earlier this week the Canadian biotech company Aeterna Zentaris announced results from a Phase II trial of its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108, in advanced endometrial cancer. This may have implications for the potential of AEZS-108 in prostate cancer too.
AEZS-108 is a hybrid molecule that combines a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin.?The synthetic peptide directs the chemotherapy agent specifically to LHRH receptor-expressing tumors. The theory is that this will result in?targeted treatment of the cancer with less damage to healthy tissue.
We aren?t going to get into the details of the endometrial cancer study. These are available in the company?s media release and also in the copy of the actual poster presented at the meeting of the European Society for Gynecologic Oncology. However, based on the data presented in the report on?this Phase II trial:
- AEZS-108 was active and well tolerated in patients with endometrial cancer at a dosage of 267 mg/m2 every 3 weeks.
- Objective responses were observed in 30.8 percent of patients.
- Stable disease was observed in 43.6 percent of patients.
- Hematologic toxicities were observed, but they were rapidly reversible, and non-hematological toxicities were also observed, but they usually not severe.
AEZS-108 is also in Phase II clinical trials for metastatic, castration-resistant prostate cancer (mCRPC). The trial protocol is available on the ClinicalTrials.gov web site. This trial is still enrolling patients.
Even if doxorubin is not the best chemotherapy drug to deliver to metastatic prostate cancer tumors using this type of delivery system, it is possible that delivering a drug like docetaxel using a similar system might have significant clinical benefit. We will need to see whether the Phase II trial of AEZS-108 in prostate cancer, referred to above, can deliver similar outcomes to the trial in endometrial cancer. The concept that one can deliver targeted chemotherapy to LHRH receptor-expressing cells does seem to be justified by the current study, and prostate cancer cells definitely do express LHRH receptors.
Like this:
Be the first to like this post.
Filed under: Drugs in development, Living with Prostate Cancer, Management Tagged: | Aeterna Zentaris, AEZS-108, doxorubicin, targeted
corset tampa bay rays lionel richie notre dame football andy murray jerusalem nadal
কোন মন্তব্য নেই:
একটি মন্তব্য পোস্ট করুন